Skip to main content
. 2023 Jun 20. Online ahead of print. doi: 10.1016/j.vaccine.2023.06.053

Fig. 1.

Fig. 1

Effective PD-1/PD-L1 ICB therapy restores tumor-induced blunted antibody responses to COVID-19 vaccination. A. Schematic graph of the experiment design. B. MC38 tumor growth curve of mice with or without anti-PD-L1 antibody treatment. C. ELISA binding assay of sera collected from mice at 10 days-post prime vaccination to SARS-CoV-2 prototype RBD. D, E. ELISA binding assays of sera collected from mice at 10 days-post boost vaccination to SARS-CoV-2 prototype RBD (D) and Omicron RBD (E). F, G. Neutralization of sera collected from mice at 10 days-post boost vaccination to SARS-CoV-2 prototype (F) and Omicron (G) variants. AUC, area under curve. NT50, neutralizing titer 50. ns, not significant. *P < 0.05 and **P < 0.01. The data are representative of two independent experiments with five to six mice per group. Error bars (B-G) indicate s.e.m..